BRPI0410767A - formulações farmacêuticas de partìcula pequena de agentes antiataque e antidemência e agentes imunossupressores - Google Patents

formulações farmacêuticas de partìcula pequena de agentes antiataque e antidemência e agentes imunossupressores

Info

Publication number
BRPI0410767A
BRPI0410767A BRPI0410767-5A BRPI0410767A BRPI0410767A BR PI0410767 A BRPI0410767 A BR PI0410767A BR PI0410767 A BRPI0410767 A BR PI0410767A BR PI0410767 A BRPI0410767 A BR PI0410767A
Authority
BR
Brazil
Prior art keywords
agents
small particle
attack
pharmaceutical formulations
dementing
Prior art date
Application number
BRPI0410767-5A
Other languages
English (en)
Inventor
Rabinow E Barrett
Jane Werling
Jamie Teresa Konkel
Mark J Doty
Christine L Rebbeck
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of BRPI0410767A publication Critical patent/BRPI0410767A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçõES FARMACêUTICAS DE PARTìCULA PEQUENA DE AGENTES ANTIATAQUE E ANTIDEMêNCIA E AGENTES IMUNOSSUPRESSORES". A presente invenção refere-se à formulação de suspensões de partícula pequena de anticonvulsivos e antidemência, particularmente carbamazepina, para uso farmacêutico. A presente invenção refere-se à formulação de suspensões de partícula pequena de agentes imunossupressores, particularmente ciclosporina, para uso farmacêutico.
BRPI0410767-5A 2003-05-19 2004-05-19 formulações farmacêuticas de partìcula pequena de agentes antiataque e antidemência e agentes imunossupressores BRPI0410767A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47158103P 2003-05-19 2003-05-19
PCT/US2004/015621 WO2004103348A2 (en) 2003-05-19 2004-05-19 Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers

Publications (1)

Publication Number Publication Date
BRPI0410767A true BRPI0410767A (pt) 2006-07-04

Family

ID=33476859

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410767-5A BRPI0410767A (pt) 2003-05-19 2004-05-19 formulações farmacêuticas de partìcula pequena de agentes antiataque e antidemência e agentes imunossupressores

Country Status (11)

Country Link
US (1) US20050244503A1 (pt)
EP (1) EP1628641A2 (pt)
JP (1) JP2006528985A (pt)
KR (1) KR20060012628A (pt)
CN (1) CN1791386A (pt)
AU (1) AU2004240640A1 (pt)
BR (1) BRPI0410767A (pt)
CA (1) CA2524538A1 (pt)
MX (1) MXPA05012467A (pt)
NO (1) NO20056020L (pt)
WO (1) WO2004103348A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230277491A1 (en) * 2020-07-31 2023-09-07 Francisco PAN-MONTOJO Pharmaceutical combination comprising glycolic acid and l-alanine

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484247B2 (ja) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
EP2266542A3 (en) * 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
EP1471887B1 (en) 2002-02-04 2010-04-21 Elan Pharma International Ltd. Nanoparticulate compositions having lysozyme as a surface stabilizer
WO2004078162A1 (en) * 2003-01-31 2004-09-16 Elan Pharma International Ltd. Nanoparticulate topiramate formulations
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
AU2004249172A1 (en) * 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
US7824697B2 (en) 2004-07-12 2010-11-02 Board Of Regents, The University Of Texas System High concentration baclofen preparations
CA2590675A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
MX2007011494A (es) * 2005-03-17 2007-12-06 Elan Pharma Int Ltd Composiciones inyectables de compuestos inmunosupresores nanoparticulados.
AU2006235487B2 (en) * 2005-04-12 2011-12-22 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
AU2006235478B2 (en) * 2005-04-12 2011-07-21 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
BRPI0600285C1 (pt) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
AU2008279129A1 (en) * 2007-07-24 2009-01-29 Nexbio, Inc. Technology for the preparation of microparticles
RU2496482C2 (ru) * 2008-03-05 2013-10-27 Бакстер Интернэшнл Инк. Композиции и способы для доставки лекарственных средств
US8969414B2 (en) * 2009-02-06 2015-03-03 Mallinckrodt Llc Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products
US20150258279A1 (en) 2008-03-18 2015-09-17 Mallinckrodt Llc Intrathecal baclofen pharmaceutical dosage forms and related delivery system
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
PE20121359A1 (es) 2009-12-10 2012-10-15 Merck Patent Gmbh Composicion farmaceutica que comprende oligopeptidos
US10307372B2 (en) * 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP2717854B1 (en) 2011-06-09 2019-01-16 Merck Patent GmbH Treatment of cancers and metastases with suspensions of cilengitide in carrier
US20140178479A1 (en) 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
EP2866792A4 (en) 2012-06-28 2016-08-17 Ansun Biopharma Inc MICROPARTICLE FORMULATIONS FOR DELIVERY TO LOWER AND CENTRAL RESPIRATORY PATHS AND METHOD OF PREPARING THEM
AU2013351934B2 (en) * 2012-11-30 2018-03-29 Insmed Incorporated Prostacylin compositions and methods for using the same
ES2860975T3 (es) 2013-10-25 2021-10-05 Insmed Inc Compuestos de prostaciclina
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
AU2016338672A1 (en) * 2015-10-16 2018-04-12 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
EP3612186A1 (en) * 2017-04-18 2020-02-26 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) * 1960-08-09 New n-heterocyclic compounds
US4608278A (en) * 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5720551A (en) * 1994-10-28 1998-02-24 Shechter; Tal Forming emulsions
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
ATE252372T1 (de) * 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
CA2277801C (en) * 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
ATE318132T1 (de) * 1998-03-30 2006-03-15 Jagotec Ag Zubereitungen enthaltend mikropartikel von wasserunlöslichen substanzen, sowie verfahren zu deren herstellung
ATE228823T1 (de) * 1998-04-18 2002-12-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
DK1169019T3 (da) * 1999-04-14 2003-06-02 Glaxo Group Ltd Farmaceutisk aerosolformulering
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230277491A1 (en) * 2020-07-31 2023-09-07 Francisco PAN-MONTOJO Pharmaceutical combination comprising glycolic acid and l-alanine

Also Published As

Publication number Publication date
CA2524538A1 (en) 2004-12-02
MXPA05012467A (es) 2006-02-22
AU2004240640A1 (en) 2004-12-02
US20050244503A1 (en) 2005-11-03
CN1791386A (zh) 2006-06-21
EP1628641A2 (en) 2006-03-01
WO2004103348A2 (en) 2004-12-02
NO20056020L (no) 2005-12-16
JP2006528985A (ja) 2006-12-28
WO2004103348A3 (en) 2005-01-06
KR20060012628A (ko) 2006-02-08

Similar Documents

Publication Publication Date Title
BRPI0410767A (pt) formulações farmacêuticas de partìcula pequena de agentes antiataque e antidemência e agentes imunossupressores
BR0210078A (pt) Composto, uso do mesmo, e, formulação farmacêutica
BR0212386A (pt) Composto, formulação farmacêutica, e, uso de um composto
BR0009083B1 (pt) derivado de amida compreendendo um núcleo de quinazolinona, processo para a preparação de um derivado de amida, composição farmacêutica, e, uso de um derivado de amida.
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
WO2001016135A3 (en) Reverse-turn mimetics and methods relating thereto
WO2005027822A3 (en) Stabilized formulations of phosphatidylserine
BR0205161A (pt) Pó de poliamida com valor do ph ajustado para empregos cosméticos
BR0011030A (pt) Composições de cicloporina substancialmente livre de óleo
BRPI0407181A (pt) Formulação farmacêutica
BR0008228A (pt) Composições de n-benzoil estaurosporinaespontaneamente dispersìveis
TW200640487A (en) Combination of XOLAIR with immunosuppressive agent
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
FR2827166B1 (fr) Mascara comprenant des particules solides
FR2827167B1 (fr) Mascara comprenant des particules solides
WO2007062338A3 (en) Solid formulations
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.
WO2005030142A8 (en) Rifalazil formulations
WO2002092010A3 (en) Reverse-turn mimetics and methods relating thereto
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
BR0210096A (pt) Composição farmacêutica contendo emoliente de fezes tal como poloxâmero e partìculas entéricas revestidas de bissacodil
BR0210632A (pt) Tratamento de doença parasìtica
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
ITRM20020119A1 (it) Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
PT1358159E (pt) Tartrato e fosfato de 3,4 diaminopiridina, as suas composições farmacêuticas e as suas utilizações

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.